assertion
Full identifier: http://purl.org/np/RAwlUKOkdB0hlnEFIKDZZnj3Llnpi16vL85c7lnRd7t4w#assertion
Minted in Nanopublication
RAwlUKOkdB
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAwlUKOkdB...#association
This association
http://www.w3.org/2000/01/rdf-schema#label
has label
(this is a literal)
"Escitalopram showed favorable pharmacokinetics and good tolerability. It is the most 5-HT-selective among SSRIs, with little or no affinity for other transmitter transporters or receptors [59]. Compared to other SSRIs, escitalopram may have weak or minimal interactions with the cytochrome P450 system [60, 61]. In a randomized, double-blind, placebo-controlled 24-week trial in OCD, escitalopram (20 mg/day) was associated with an increase in response rate compared to placebo after 12 weeks. Other placebo-controlled studies consistently showed escitalopram-related treatment response [25, 30]. 20 mg/day escitalopram has also been associated with better OCD symptom remission compared to 40 mg/day paroxetine or placebo at week 12 [30]. Three different escitalopram dosages (5, 10, and 20 mg/day) were compared with a fixed, 20 mg/day dose of paroxetine in a 12-week study, in which escitalopram showed both greater efficacy and better tolerability [62]."
.
Vincent Emonet,
16 Sep 2022, 11:53:46 UTC
References
|
|
|
assertion
|
|
|
Vincent Emonet
|
2022-09-16T11:53:46.825Z
|